Bookmark and share the address of UKRAINE ENGLISH NEWS on your social bookmarking website
Most users ever online was 229 on Sat Aug 08, 2015 11:03 pm
Reported Tech Insider .
Medicines are struggling right of all known strains of hepatitis C and provide almost 100% of the first effects after 3 months of regular use.
Epclusa has sofosbuvir and velpatasvira. Both substances have been developed biopharmaceutical company Gilead Sciences. Sofosbuvir been approved for use in 2013 and received permission velpatasvir FDA only recently.
In a world suffering from hepatitis 130-150 million people. The disease is divided into six major genotypes, or strains, based on which doctors picked by appropriate treatment. Epclusa just struggling with all kinds of hepatitis C. The patient need only take one tablet daily for 12 weeks.
After receiving Epclusa in 95-99% of patients with cirrhosis has not yet developed or is in the early stages of the virus in the blood was found. Patients with serious disorders of the liver Epclusa used together with ribavirin treatment and the percentage was 94%.
Cure Gilead will be available through a few great prices. Epclusa course will cost $ 74,760. This is $ 10,000 cheaper medicines on the basis of only sofosbuvir.
ukr.obozrevatel.com In Ukrainian/український